{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:11Z","timestamp":1785743171498,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02435-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:44:14Z","timestamp":1783097054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Viviana","family":"Nociti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cesarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsina","family":"Casalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Torri","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Marcello","family":"Solaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2435_CR1","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F et al (2020) The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health 5:e551\u2013e567. https:\/\/doi.org\/10.1016\/S2468-2667(20)30190-0","journal-title":"Lancet Public Health"},{"key":"2435_CR2","unstructured":"Italiana E, Guidetti V, Savi L (2013) Classificazione Internazionale delle Cefalee Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3 rd edition"},{"key":"2435_CR3","doi-asserted-by":"publisher","unstructured":"Nociti V, Romozzi M (2025) Anticipating clinical onset in multiple sclerosis: challenges and opportunities. J Pers Med 15. https:\/\/doi.org\/10.3390\/jpm15120598","DOI":"10.3390\/jpm15120598"},{"key":"2435_CR4","doi-asserted-by":"publisher","unstructured":"Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD (2025) Migraine and tension-type headache in multiple sclerosis: a two-year, prospective, longitudinal, controlled study. Mult Scler Relat Disord 103. https:\/\/doi.org\/10.1016\/j.msard.2025.106664","DOI":"10.1016\/j.msard.2025.106664"},{"key":"2435_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104152","author":"S Mrabet","year":"2022","unstructured":"Mrabet S, Wafa M, Giovannoni G (2022) Multiple sclerosis and migraine: Links, management and implications. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2022.104152. 68:","journal-title":"Mult Scler Relat Disord"},{"key":"2435_CR6","doi-asserted-by":"publisher","unstructured":"Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD (2025) Association between multiple sclerosis lesion location, migraine and tension-type headache: a cross-sectional study. J Clin Neurosci 136. https:\/\/doi.org\/10.1016\/j.jocn.2025.111250","DOI":"10.1016\/j.jocn.2025.111250"},{"key":"2435_CR7","doi-asserted-by":"publisher","first-page":"448963","DOI":"10.3389\/FPHAR.2019.00363\/BIBTEX","volume":"10","author":"D Scuteri","year":"2019","unstructured":"Scuteri D, Adornetto A, Rombol\u00e0 L et al (2019) New trends in migraine pharmacology: Targeting calcitonin gene\u2013related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 10:448963. https:\/\/doi.org\/10.3389\/FPHAR.2019.00363\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"2435_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.690683","author":"FG Freitag","year":"2021","unstructured":"Freitag FG (2021) Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge. Front Pain Res. https:\/\/doi.org\/10.3389\/fpain.2021.690683. 2:","journal-title":"Front Pain Res"},{"key":"2435_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21:284\u2013294. https:\/\/doi.org\/10.1016\/S1474-4422(21)00409-9","journal-title":"Lancet Neurol"},{"key":"2435_CR10","doi-asserted-by":"publisher","unstructured":"Romozzi M, Lokhandwala A, Vollono C et al (2024) An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine. Cephalalgia 44. https:\/\/doi.org\/10.1177\/03331024241262751","DOI":"10.1177\/03331024241262751"},{"key":"2435_CR11","doi-asserted-by":"publisher","unstructured":"Iannone LF, Silvestro M, Munaf\u00f2 A, Romozzi M, Geppetti P, Russo A. The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. Headache. 2026;00:1-16. https:\/\/doi.org\/10.1111\/head.70114","DOI":"10.1111\/head.70114"},{"key":"2435_CR12","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf"},{"key":"2435_CR13","unstructured":"Study Details | NCT02964338 | A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02964338. Accessed 7 Jun 2026"},{"key":"2435_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Munaf\u00f2 A, Burgalassi A et al (2025) Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review. Headache 65:342\u2013352. https:\/\/doi.org\/10.1111\/head.14903","journal-title":"Headache"},{"key":"2435_CR15","doi-asserted-by":"publisher","unstructured":"Iannone LF, Piella EM, Montisano DA et al (2026) Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study). Cephalalgia 46. https:\/\/doi.org\/10.1177\/03331024251414659","DOI":"10.1177\/03331024251414659"},{"key":"2435_CR16","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf"},{"key":"2435_CR17","doi-asserted-by":"publisher","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ (2022) New Generation gepants: migraine acute and preventive medications. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11061656","DOI":"10.3390\/jcm11061656"},{"key":"2435_CR18","doi-asserted-by":"publisher","unstructured":"Assas BM, Pennock JI, Miyan JA (2014) Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. Front Neurosci 8. https:\/\/doi.org\/10.3389\/FNINS.2014.00023","DOI":"10.3389\/FNINS.2014.00023"},{"key":"2435_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/2042098611406318","volume":"2","author":"MG Tovey","year":"2011","unstructured":"Tovey MG, Lallemand C (2011) Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2:113\u2013128. https:\/\/doi.org\/10.1177\/2042098611406318","journal-title":"Ther Adv Drug Saf"},{"key":"2435_CR20","unstructured":"FDA Prescribing Information for QULIPTA (atogepant) tablets (2021) U.S. Food and Drug Administration"},{"key":"2435_CR21","doi-asserted-by":"publisher","unstructured":"Nociti V, Romozzi M, Annovazzi P et al (2025) Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies. J Neurol Sci 469. https:\/\/doi.org\/10.1016\/j.jns.2025.123392","DOI":"10.1016\/j.jns.2025.123392"},{"key":"2435_CR22","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1177\/13524585221096353","volume":"28","author":"A Gonzalez-Martinez","year":"2022","unstructured":"Gonzalez-Martinez A, Bose G, Chitnis T (2022) Anti-CGRP therapies for migraine in multiple sclerosis patients. Multiple Scler J 28:2149\u20132150. https:\/\/doi.org\/10.1177\/13524585221096353","journal-title":"Multiple Scler J"},{"key":"2435_CR23","unstructured":"Study Details | NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06323928?cond=migraine&term=PROCEED&rank=1. Accessed 7 Jun 2026"},{"key":"2435_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"2435_CR25","doi-asserted-by":"publisher","unstructured":"Olesen J (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2435_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"2435_CR27","unstructured":"jamovi - open statistical software for the desktop and cloud. https:\/\/www.jamovi.org\/. Accessed 24 Nov 2025"},{"key":"2435_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7224\/1537-2073.2023-013","volume":"26","author":"A Mason","year":"2024","unstructured":"Mason A, Fragapane L, Toledo-Nieves Z et al (2024) Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies for the Treatment of Migraines in Individuals With Multiple Sclerosis. Int J MS Care 26:104\u2013107. https:\/\/doi.org\/10.7224\/1537-2073.2023-013","journal-title":"Int J MS Care"},{"key":"2435_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/S00415-025-13419-Z","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Fiorentini G et al (2025) Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study. J Neurol 272:683. https:\/\/doi.org\/10.1007\/S00415-025-13419-Z","journal-title":"J Neurol"},{"key":"2435_CR30","doi-asserted-by":"publisher","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F (2024) CGRP-targeted medication in chronic migraine - systematic review. The journal of headache and pain 25:51-. https:\/\/doi.org\/10.1186\/S10194-024-01753-Y","DOI":"10.1186\/S10194-024-01753-Y"},{"key":"2435_CR31","doi-asserted-by":"publisher","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23. https:\/\/doi.org\/10.1186\/S10194-022-01498-6","DOI":"10.1186\/S10194-022-01498-6"},{"key":"2435_CR32","doi-asserted-by":"publisher","unstructured":"Woolf CJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain 152. https:\/\/doi.org\/10.1016\/j.pain.2010.09.030","DOI":"10.1016\/j.pain.2010.09.030"},{"key":"2435_CR33","doi-asserted-by":"publisher","first-page":"1703876","DOI":"10.3389\/FNEUR.2025.1703876","volume":"16","author":"C Sanabria-Gago","year":"2025","unstructured":"Sanabria-Gago C, Fern\u00e1ndez L\u00e1zaro I, Heredia P et al (2025) SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway\u2013targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials. Front Neurol 16:1703876. https:\/\/doi.org\/10.3389\/FNEUR.2025.1703876","journal-title":"Front Neurol"},{"key":"2435_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/S00415-025-13177-Y","volume":"272","author":"MC Garc\u00eda-Castillo","year":"2025","unstructured":"Garc\u00eda-Castillo MC, Sierra-Menc\u00eda \u00c1, Caronna E et al (2025) Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies. J Neurol 2025 272:6. https:\/\/doi.org\/10.1007\/S00415-025-13177-Y","journal-title":"J Neurol 2025"},{"key":"2435_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jneuroim.2014.03.008","volume":"271","author":"C Sardi","year":"2014","unstructured":"Sardi C, Zambusi L, Finardi A et al (2014) Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis. J Neuroimmunol 271:18\u201329. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.03.008","journal-title":"J Neuroimmunol"},{"key":"2435_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ et al (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache 64:333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"key":"2435_CR37","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ana.25247","volume":"83","author":"G Disanto","year":"2018","unstructured":"Disanto G, Zecca C, MacLachlan S et al (2018) Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol 83:1162\u20131173. https:\/\/doi.org\/10.1002\/ana.25247","journal-title":"Ann Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02435-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:01:40Z","timestamp":1785740500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02435-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2435"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02435-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki (1975). Ethical approval was obtained from the Ethics Committee of Universit\u00e0 Cattolica del Sacro Cuore. All participants provided written informed consent authorizing the use of their clinical and radiological data for research purposes.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CV has received research support and personal fees from Angelini Pharma, Lundbeck, Jazz Pharmaceuticals, Eisai, and UCB; no other conflicts of interest related to this work are present. GAM is an Advisory Board member of Sanofi-Genzyme, Merck-Serono, Novartis, Roche, Alexion, Amgen and received honoraria for speaking or consultation fees from Almirall, Amgen, Alexion, Merck Serono, Neuraxpharm, Novartis, Sanofi-Genzyme, Roche, and BMS. She is the principal investigator in clinical trials for Merck Serono, Novartis, Roche, Sanofi-Genzyme, and BMS. LFI received financial support, consulting fees for the participation in advisory boards and support for attending meetings from: Teva, Eli Lilly, Lundbeck, Pfizer and AbbVie; he is Associate Editor for Frontiers in Neurology and junior editor of Cephalalgia and Cephalalgia report. MR has received research support and personal fees from Angelini Pharma, Lundbeck, Jazz Pharmaceuticals, Eisai, and UCB; no other conflicts of interest related to this work are present. FP received consulting fees for the participation in advisory boards from Organon, Pfizer and Lundbeck and support for attending meetings from Abbvie, Pfizer, Lundbeck, Teva, Storz. No conflicts of interest relevant to this work are reported. VT has received honoraria, travel grant, research support from Almirall, Viatris, Novartis, Roche, Biogen, Janssen, Juvis\u00e9, Merck, Alexion, Horizon, Amgen, Bristol Myers Squibb, Lundbeck, Sanofi.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"195"}}